Twist Bioscience Corporation Research and Development Expense
Twist Bioscience Corporation (TWST) reported Research and Development Expense of $18.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-03
- Twist Bioscience Corporation research and development expense for the quarter ending 2026-06-30 was $18.02M, a 0.12% decline year-over-year.
- Twist Bioscience Corporation research and development expense for the quarter ending 2026-03-31 was $19.70M, a 17.65% decline year-over-year.
- Twist Bioscience Corporation research and development expense for the quarter ending 2025-12-31 was $17.13M, a 19.60% decline year-over-year.
- Twist Bioscience Corporation research and development expense for the quarter ending 2025-09-30 was $17.01M, a 19.49% decline year-over-year.
- Twist Bioscience Corporation research and development expense for fiscal 2025 was $80.28M, a 11.63% decline from fiscal 2024.
- Twist Bioscience Corporation research and development expense for fiscal 2024 was $90.85M, a 15.01% decline from fiscal 2023.
- Twist Bioscience Corporation research and development expense for fiscal 2023 was $106.89M, a 11.15% decline from fiscal 2022.
- Twist Bioscience Corporation research and development expense for fiscal 2022 was $120.31M, a 74.18% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.02M 10-Q · filed 2026-08-03 | $37.72M derived: sum of 2 quarters · filed 2026-08-03 | $54.85M 10-Q · filed 2026-08-03 | $71.86M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $19.70M 10-Q · filed 2026-05-04 | $36.83M 10-Q · filed 2026-05-04 | $53.84M derived: sum of 3 quarters · filed 2026-05-04 | $71.89M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $17.13M 10-Q/A · filed 2026-02-26 | $34.14M derived: sum of 2 quarters · filed 2026-02-26 | $52.19M derived: sum of 3 quarters · filed 2026-08-03 | $76.11M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-09-30 | $17.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $35.06M derived: sum of 2 quarters · filed 2026-08-03 | $58.98M derived: sum of 3 quarters · filed 2026-08-03 | $80.28M 10-K · filed 2025-11-17 |
| 2025-06-30 | $18.05M 10-Q · filed 2026-08-03 | $41.96M derived: sum of 2 quarters · filed 2026-08-03 | $63.27M 10-Q · filed 2026-08-03 | $84.41M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $23.92M 10-Q · filed 2026-05-04 | $45.22M 10-Q · filed 2026-05-04 | $66.36M derived: sum of 3 quarters · filed 2026-05-04 | $88.83M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $21.31M 10-Q/A · filed 2026-02-26 | $42.44M derived: sum of 2 quarters · filed 2026-02-26 | $64.91M derived: sum of 3 quarters · filed 2026-02-26 | $89.06M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-09-30 | $21.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $43.60M derived: sum of 2 quarters · filed 2025-11-17 | $67.75M derived: sum of 3 quarters · filed 2025-11-17 | $90.85M 10-K · filed 2025-11-17 |
| 2024-06-30 | $22.47M 10-Q · filed 2025-08-04 | $46.62M derived: sum of 2 quarters · filed 2025-08-04 | $69.72M 10-Q · filed 2025-08-04 | $93.46M derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-03-31 | $24.15M 10-Q · filed 2025-05-05 | $47.25M 10-Q · filed 2025-05-05 | $70.99M derived: sum of 3 quarters · filed 2025-11-17 | $95.52M derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-12-31 | $23.10M 10-Q · filed 2025-02-03 | $46.84M derived: sum of 2 quarters · filed 2025-11-17 | $71.37M derived: sum of 3 quarters · filed 2025-11-17 | $98.75M derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-09-30 | $23.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $48.27M derived: sum of 2 quarters · filed 2025-11-17 | $75.65M derived: sum of 3 quarters · filed 2025-11-17 | $106.89M 10-K · filed 2025-11-17 |
| 2023-06-30 | $24.53M 10-Q · filed 2024-08-02 | $51.91M derived: sum of 2 quarters · filed 2024-08-02 | $83.15M 10-Q · filed 2024-08-02 | $112.75M derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-03-31 | $27.38M 10-Q · filed 2024-05-02 | $58.62M 10-Q · filed 2024-05-02 | $88.23M derived: sum of 3 quarters · filed 2024-11-18 | $125.07M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-12-31 | $31.24M 10-Q · filed 2024-02-02 | $60.85M derived: sum of 2 quarters · filed 2024-11-18 | $97.69M derived: sum of 3 quarters · filed 2024-11-18 | $128.92M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-09-30 | $29.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-18 | $66.45M derived: sum of 2 quarters · filed 2024-11-18 | $97.68M derived: sum of 3 quarters · filed 2024-11-18 | $120.31M 10-K · filed 2024-11-18 |
| 2022-06-30 | $36.84M 10-Q · filed 2023-08-07 | $68.07M derived: sum of 2 quarters · filed 2023-08-07 | $90.70M 10-Q · filed 2023-08-07 | $110.14M derived: sum of 4 quarters · filed 2023-11-21 |
| 2022-03-31 | $31.23M 10-Q · filed 2023-05-08 | $53.86M 10-Q · filed 2023-05-08 | $73.30M derived: sum of 3 quarters · filed 2023-11-21 | $93.14M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-12-31 | $22.63M 10-Q · filed 2023-02-07 | $42.07M derived: sum of 2 quarters · filed 2023-11-21 | $61.91M derived: sum of 3 quarters · filed 2023-11-21 | $77.70M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-09-30 | $19.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | $39.28M derived: sum of 2 quarters · filed 2023-11-21 | $55.07M derived: sum of 3 quarters · filed 2023-11-21 | $69.07M 10-K · filed 2023-11-21 |
| 2021-06-30 | $19.84M 10-Q · filed 2022-08-08 | $35.63M derived: sum of 2 quarters · filed 2022-08-08 | $49.63M 10-Q · filed 2022-08-08 | $61.27M derived: sum of 4 quarters · filed 2023-06-05 |
| 2021-03-31 | $15.79M 10-Q · filed 2022-05-06 | $29.79M 10-Q · filed 2022-05-06 | $41.43M derived: sum of 3 quarters · filed 2023-06-05 | $51.87M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-12-31 | $14.00M 10-Q · filed 2022-02-09 | $25.64M derived: sum of 2 quarters · filed 2023-06-05 | $36.08M derived: sum of 3 quarters · filed 2023-06-05 | $46.71M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-09-30 | $11.64M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | $22.08M derived: sum of 2 quarters · filed 2023-06-05 | $32.71M derived: sum of 3 quarters · filed 2023-06-05 | $43.01M 10-K/A · filed 2023-06-05 |
| 2020-06-30 | $10.44M 10-Q · filed 2021-08-09 | $21.07M derived: sum of 2 quarters · filed 2021-08-09 | $31.37M 10-Q · filed 2021-08-09 | $41.87M derived: sum of 4 quarters · filed 2021-11-23 |
| 2020-03-31 | $10.63M 10-Q · filed 2021-05-07 | $20.93M 10-Q · filed 2021-05-07 | $31.42M derived: sum of 3 quarters · filed 2021-11-23 | $40.43M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-12-31 | $10.30M 10-Q · filed 2021-02-09 | $20.79M derived: sum of 2 quarters · filed 2021-11-23 | $29.80M derived: sum of 3 quarters · filed 2021-11-23 | $38.71M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-09-30 | $10.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-23 | $19.50M derived: sum of 2 quarters · filed 2021-11-23 | $28.41M derived: sum of 3 quarters · filed 2021-11-23 | $35.68M 10-K · filed 2021-11-23 |
| 2019-06-30 | $9.01M 10-Q · filed 2020-08-12 | $17.91M derived: sum of 2 quarters · filed 2020-08-12 | $25.19M 10-Q · filed 2020-08-12 | $31.25M derived: sum of 4 quarters · filed 2020-11-27 |
| 2019-03-31 | $8.91M 10-Q · filed 2020-05-13 | $16.18M 10-Q · filed 2020-05-13 | $22.25M derived: sum of 3 quarters · filed 2020-11-27 | $27.51M derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-12-31 | $7.27M 10-Q · filed 2020-02-10 | $13.34M derived: sum of 2 quarters · filed 2020-11-27 | $18.61M derived: sum of 3 quarters · filed 2020-11-27 | $23.32M derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-09-30 | $6.07M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-27 | $11.33M derived: sum of 2 quarters · filed 2020-11-27 | $16.04M derived: sum of 3 quarters · filed 2020-11-27 | $20.35M 10-K · filed 2020-11-27 |
| 2018-06-30 | $5.27M 10-Q · filed 2019-08-09 | $9.98M derived: sum of 2 quarters · filed 2019-08-09 | $14.28M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $4.71M 10-Q · filed 2019-05-02 | $9.01M 10-Q · filed 2019-05-02 | ||
| 2017-12-31 | $4.30M 10-Q · filed 2019-02-11 | |||
| 2017-09-30 | $19.17M 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |